Loading
A four-stain test that shows whether a womb cancer has lost its DNA spell-checker, which makes immunotherapy likely to work.
Approved by the FDA in August 2021 together with dostarlimab for mismatch-repair-deficient (dMMR) recurrent or advanced endometrial cancer, the first immunohistochemistry companion diagnostic for mismatch-repair status. MMR immunohistochemistry is cheap, fast and available in every pathology laboratory, and is the recommended first-line test in endometrial and colorectal cancer, where it also serves as universal screening for Lynch syndrome. Where results are equivocal, PCR or NGS-based microsatellite-instability testing is used. Immunotherapy responses in dMMR tumours are among the most durable in oncology, so the stain has outsized consequences for a patient.
Four immunohistochemical stains (MLH1, PMS2, MSH2, MSH6) read together; loss of nuclear staining for any protein classifies the tumour as mismatch-repair deficient.
1.VENTANA MMR RxDx Panel slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| US | 2021 | Companion diagnostic for dostarlimab in dMMR endometrial cancer |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
It tells the pathologist which pancreatic cancers to test for the one immunotherapy-responsive subgroup and how.
It is the reference for what a colorectal molecular report must contain, and the document that turned extended RAS from a trial finding into a requirement.
It is the evidence behind universal mismatch repair testing of every colorectal cancer, which is now standard in most guidelines and which, as a by-product, identifies everyone eligible for immunotherapy.
Query for this drug: (TITLE:"VENTANA MMR RxDx Panel" OR ABSTRACT:"VENTANA MMR RxDx Panel" OR TITLE:"VENTANA MMR RxDx" OR ABSTRACT:"VENTANA MMR RxDx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VENTANA MMR RxDx Panel, not a curated reading list.
Shares Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO, Companion diagnostics, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma and the tag test.
Shares Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO, Companion diagnostics, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma and the tag test.
Shares Companion diagnostics, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma and the tag test.
Shares Companion diagnostics, Histopathology & immunohistochemistry, Roche / Genentech, Triple-negative breast cancer (TNBC) and the tag test.
Shares Companion diagnostics, Histopathology & immunohistochemistry, Roche / Genentech, Triple-negative breast cancer (TNBC) and the tag test.
Shares Companion diagnostics, Histopathology & immunohistochemistry, Triple-negative breast cancer (TNBC), Pembrolizumab and the tag test.
Shares Companion diagnostics, Histopathology & immunohistochemistry, Roche / Genentech, Gallbladder cancer and the tag test.
Shares Companion diagnostics, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma and the tag test.